Callio Therapeutics
Latest round
- Series A
Last raised
- Mar 2025
Total raised
- $187M
Investors
- 10
About Callio Therapeutics
Callio Therapeutics specializes in advancing innovative biopharmaceutical solutions, focusing on the development of therapies for serious diseases, particularly in the oncology space. Founded in 2025 by CEO Piers Ingram and CSO Jerome Boyd-Kirkup, Callio Therapeutics is focused on developing groundbreaking biopharmaceutical therapies. The company is headquartered in Seattle, US. The company was founded by individuals with extensive experience in the biopharmaceutical industry, although specific names are not disclosed. Callio Therapeutics specializes in delivering innovative solutions within the biopharmaceutical sector, focusing on therapies designed to treat serious diseases, particularly in oncology. Their core offerings include a pipeline of drug candidates aimed at addressing significant unmet medical needs, enhancing treatment efficiency and effectiveness. The company targets markets in North America and Europe, establishing partnerships with both healthcare providers and research institutions to facilitate the development and distribution of their therapies. Callio Therapeutics generates revenue primarily through partnerships and collaborations in the biopharmaceutical sector, including agreements with research institutions and healthcare organizations. Callio Therapeutics plans to develop and launch new therapies within its pipeline, specifically targeting oncology-related treatments set for clinical trial phases in the next 12 to 18 months. In addition, the company aims to expand its presence into European markets by 2026.
Who invested in Callio Therapeutics
10 investors across 1 round
See all investors in Callio Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 3, 2025
Amount
$187M
Investors
Questions about Callio Therapeutics
Who invested in Callio Therapeutics?
Callio Therapeutics has 10 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Callio Therapeutics raised?
Callio Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Callio Therapeutics last raise money?
Callio Therapeutics's most recent round on record is a Series A, in Mar 2025.
What does Callio Therapeutics do?
Callio Therapeutics specializes in advancing innovative biopharmaceutical solutions, focusing on the development of therapies for serious diseases, particularly in the oncology space.
Where is Callio Therapeutics headquartered?
Callio Therapeutics is headquartered in Seattle, US.
Which VCs invest in companies like Callio Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Callio Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Callio Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.